TGFB1 and neoplasm: Grauel et al. [31] found that although myCAFs promoted tumor stages and deteriorated long-term outcomes, after remodeling CAF dynamics by neutralization of TGF-β, CAFs develop productive antitumor immunity and better efficacy of PD-1 immunotherapy, especially antigen-presenting CAFs (apCAFs).